Timing of paclitaxel treatment in pre‐operative or post‐operative does not affect survival in breast cancer patients

BACKGROUND: Two epirubicin and paclitaxel‐based neoadjuvant chemotherapy regimens were compared in breast cancer patients. METHODS: We enrolled 309 breast cancer patients who received two types of regimens: cyclophosphamide + epirubicin dose‐dense neoadjuvant chemotherapy followed by sequential post...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jiayu, Chen, Shanshan, Xu, Binghe, Yuan, Peng, Ma, Fei, Li, Qing, Zhang, Pin, Cai, Ruigang, Fan, Ying, Luo, Yang, Li, Qiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415454/
https://www.ncbi.nlm.nih.gov/pubmed/28402606
http://dx.doi.org/10.1111/1759-7714.12433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415454/
https://www.ncbi.nlm.nih.gov/pubmed/28402606
http://dx.doi.org/10.1111/1759-7714.12433

Ejemplares similares